Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia

Gernot Schabbauer1, Ulrich Matt, Philipp Günzl

  • 1Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Austrian Academy of Sciences, Vienna, Austria. gernot.schabbauer@meduniwien.ac.at

Insights

Removing PTEN in myeloid cells enhances PI3K activity, reducing inflammation and improving survival in mice infected with Streptococcus pneumoniae. This study reveals PTEN

Area of Science:

  • Immunology
  • Cell Biology
  • Microbiology

Background:

  • Phosphatidylinositol 3-kinase (PI3K) is crucial for immune cell chemotaxis and pathogen elimination.
  • PI3K signaling also modulates immune responses, potentially limiting acute inflammation.
  • The role of the PI3K pathway and its antagonist, PTEN, in bacterial infections remains unclear.

Purpose of the Study:

  • To investigate the role of PTEN in myeloid cells during Streptococcus pneumoniae infection.
  • To understand how PTEN deficiency impacts the immune response and disease severity.

Main Methods:

  • Utilized genetically modified mice lacking myeloid cell-specific PTEN.
  • Assessed survival rates and disease severity following S. pneumoniae infection.
  • Analyzed inflammatory responses in macrophages in vitro and in vivo.
  • Quantified neutrophil influx and bacterial load (CFUs) in lung tissues.

Main Results:

  • PTEN-deficient mice showed reduced disease severity and prolonged survival.
  • Pulmonary inflammation and macrophage inflammatory responses were significantly reduced.
  • Neutrophil influx into the lungs was unexpectedly impaired.
  • Phagocytosis by PTEN-deficient alveolar macrophages was enhanced, maintaining lung bacterial clearance.
  • Reduced tissue injury was observed in PTEN-deficient mice.

Conclusions:

  • Absence of myeloid cell PTEN enhances PI3K activity, dampening pulmonary inflammation.
  • Impaired neutrophil influx coupled with augmented macrophage phagocytosis leads to improved outcomes.
  • Targeting PTEN in myeloid cells may represent a therapeutic strategy for bacterial pneumonia.

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
4.7K
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
24
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24